ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced its...
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced its...
BURLINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused...
Company to host conference call and webcast on Wednesday, August 28th at 8:30am EDT LYON, France, August 7, 2024 --...
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic...
NEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical...
Results Release and Webinar Discussion on Morning of August 14, 2024MISSISSAUGA, Ontario, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems...
Second-quarter 2024 net sales of $14.6 million Rezdiffra™ (resmetirom) coverage in place for more than 50 percent of commercial lives;...
BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused...
Management to host conference call and webcast at 8:30am ETPITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI),...
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage...
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D., has...
On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical...
– Phase 3 LUGANO pivotal non-inferiority clinical trial of DURAVYU™ in wet AMD on track for first patient dosing in...
-Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis--Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proceeds...
Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall development timelines following...
NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action...
Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024Selected by Food...
LOS ANGELES, Aug. 7, 2024 /PRNewswire/ -- SprintRay is excited to announce The Midas Restoration Tour, an event series to...
PALO ALTO, CA / ACCESSWIRE / August 7, 2024 / Bioz, Inc., a pioneer in AI-driven research solutions, is excited...
STOCKHOLM, SE / ACCESSWIRE / August 07, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a...